Soluble Whey Protein Agglomerates for GLP-1 Metabolic Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a persistent need in the food industry for nutritional solutions that effectively address conditions linked to GLP-1 blood levels, including obesity, diabetes, non-alcoholic fatty liver disease, cardiovascular events, muscle atrophy, and other metabolic disorders, as existing treatments are inadequate in improving insulin secretion, satiety, glycemic control, and muscle microvascular perfusion.
Innovation Solution
Agglomerates of soluble whey protein aggregates (AWA) are developed to increase GLP-1 levels, formulated by denaturing whey proteins under specific pH and temperature conditions, followed by agglomeration, to enhance satiety, insulin secretion, and improve metabolic health outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutritional solutions are used, then basic nutritional needs are met, but they are inadequate in improving insulin secretion, satiety, glycemic control, and muscle microvascular perfusion
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of whey protein through controlled heat treatment (68-180°C) and pH adjustment (6-9), transforming it into agglomerates of soluble whey protein aggregates with enhanced biological activity. This altered protein structure enables superior GLP-1 stimulation compared to conventional whey protein products.
Solution Approach 2:
The invention creates a composite functional protein aggregate system where denatured whey protein aggregates are formed through specific processing conditions, resulting in a multi-functional material that simultaneously stimulates GLP-1 secretion, improves satiety, enhances insulin secretion, and supports muscle health - addressing multiple metabolic conditions with a single product.
2Reliability
If existing GLP-1 treatments are used, then some metabolic conditions can be managed, but the solutions are inadequate and require further improvement
Solution Approach 1:
The patent employs self-service by utilizing the whey protein's own structural properties and responding to its inherent denaturation behavior under heat and pH stress to form functional aggregates. The process leverages the protein's natural aggregation tendencies rather than requiring complex external agents or multi-step synthesis, simplifying manufacturing while maintaining high GLP-1 stimulatory activity.
3Quantity of substance
If whey protein is denatured under specific conditions, then GLP-1 levels increase, but the protein structure changes
Solution Approach 1:
The patent deliberately applies parameter changes through controlled heat treatment (68-180°C) and pH adjustment (6-9) to denature whey protein and form aggregates. This controlled structural transformation is necessary to achieve enhanced GLP-1 stimulation, and the process parameters are optimized to ensure the aggregates maintain stability and solubility while providing the desired biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AWA increases GLP-1 levels, leading to reduced body weight, improved glycemic control, enhanced insulin secretion, and reduced risk of metabolic disorders such as diabetes and cardiovascular events, while promoting muscle health.
Implementation Method 1
denaturing whey proteins under specific pH and temperature conditions
Implementation Method 2
followed by agglomeration
Data Source
AI summary
The present invention relates to agglomerates of soluble whey protein aggregates for use in the treatment and/or prevention of one or more conditions linked to GLP-1 blood levels in a human subject.